Pancreatic cancer is one of the deadliest types of cancer, with fewer than 13% of people diagnosed with it surviving for more ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

Cancer vaccines harness the power of the immune system to stop tumors in their tracks. They work a little differently than ...

The five-year survival rate of people diagnosed with pancreatic cancer is currently 13 percent. Two breakthroughs are ...

A team of Yale researchers recently published promising results from a clinical trial testing the effectiveness of a new ...

The new medication is personalized for each patient's tumor, mobilizing the immune system to attack cancer cells with few ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

Cash and cash equivalents at the end of fourth quarter of 2024 of approximately $60.0 million; secured up to €57.5 million in debt financing from the European Investment Bank (EIB); the company ...

The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate ...

"If you can do this in pancreas cancer, theoretically you may be able to develop therapeutic vaccines for other cancer types." ...

Although the findings are promising, these vaccines are still in the early stages of testing." The team is planning a larger ...